Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Terumo To Launch New Blood Pressure Monitor Targeted At Females

This article was originally published in PharmAsia News

Executive Summary

Japanese medical device maker Terumo announced Jan. 8 that the company plans a February launch of Premiage P400, a blood pressure monitor that is applied on the wrist. According to the company, the device will be targeted at females in their 50s who are most likely to develop lifestyle diseases such as hypertension. Priced at around ¥10,000, the product also comes in four colors, including pink and beige. (Click here for more - Japanese language

You may also be interested in...

Terumo Acquires 5% of Fuji Pharma To Grow Drug/Device Combo Product Business

TOKYO - Japanese device maker Terumo Corp. reached an agreement to purchase 5 percent of Fuji Pharma common shares for jointly developing a drug and device combination product business in Japan - the first such convergence undertaking in a country where the government in the past administered the pharmaceutical and medical device markets almost separately

Angelini Sets Up In Germany As It Unveils ThermaCare Plans

Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts